CD69 is independently prognostic in chronic lymphocytic leukemia: A comprehensive clinical and biological profiling study

Haematologica

Volumn 97, Issue 2, 2012, Pages 279-287

  Poeta, Giovanni Del ^a   Principe, Maria Ilaria Del ^a   Zucchetto, Antonella ^b   Luciano, Fabrizio ^a   Buccisano, Francesco ^a   Rossi, Francesca Maria ^b   Bruno, Antonio ^a   Biagi, Annalisa ^a   Bulian, Pietro ^b   Maurillo, Luca ^a   Neri, Benedetta ^a   Bomben, Riccardo ^b   Simotti, Cristina ^a   Coletta, Angela Maria ^a   Bo, Michele Dal ^b   de Fabritiis, Paolo ^a   Venditti, Adriano ^a   Gattei, Valter ^b   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Chronic lymphocytic leukemia; Immunophenotyping; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; CD23 ANTIGEN; CD38 ANTIGEN; CD69 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; COHORT STUDIES; FEMALE; HUMANS; LECTINS, C-TYPE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VIDARABINE;

EID: 84856485321     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.052829     Document Type: Article

References (43)

1. Zwiebel JA, Cheson BD. Chronic lympho-cytic leukemia: Staging and prognostic factors. Semin Oncol. 1998;25(1):42-59.
2. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206.
3. Rai K. A critical analysis of staging in CLL. In Gale R, Rai K (eds): Chronic Lymphocytic Leukemia. Recent Progress and Future Directions. New York, NY, Liss. 1987;p 253.
4. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62(3):567-75.
5. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S. The serum b2-microglobulin level is more powerful than stage in predicting response and survival in chronic lym-phocytic leukemia. Blood. 1995;86:Abstract 606.
6. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood. 1996;88(11):4259-64.
7. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-6.
8. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98(9):2633-9.
9. Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111(2);865-73.
10. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7.
11. Hamblin TJ, Davis Z, Gardiner A, Oscier DG and Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-54.
12. Degan M, Bomben R, Dal Bo M, Zucchetto A, Nanni P, Rupolo M, et al. Analysis of IgV gene mutations in B cell chronic lymphocyt-ic leukaemia according to antige-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol. 2004;126(1):29-42.
13. Krober A, Seller T, Benner A, Bullinger L, Brückle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410-6.
14. Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A, et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood. 2007;109(7):2989-98.
15. Capello D, Guarini A, Berra E, Mauro FR, Rossi D, Ghia E, et al. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. Leukemia. 2004;18(12):1941-7.
16. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z and Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood. 2000;95(7):2455-7.
17. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98(1):181-6.
18. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobu-lin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18):1764-75.
19. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;35(9):893-901.
20. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lym-phocytic leukaemia. Lancet. 2004;363 (9403):105-11.
21. Del Principe MI, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, et al. Clinical significance of ZAP-70 protein expession in B-cell chronic lymphocytic leukemia. Blood. 2006;108(3):853-61.
22. Zucchetto A, Bomben R, Dal Bo M, Nanni P, Bulian P, Rossi FM, et al. ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations. Cytometry B Clin Cytom. 2006;70(4):284-92.
23. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, et al. B-cell chronic lym-phocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002; 99(11):4087-93.
24. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today. 1994;15(10):479-83.
25. Marzio R, Manuel J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol. 1999;21(3):365-82.
26. Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells. 1994; 12(5):456-65.
27. D'Arena G, Musto P, Nunziata G, Cascavilla N, Savino L, Pistolese G. CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker? Haematologica. 2001;86(9):995-6.
28. Del Poeta G, Del Principe MI, Consalvo MA, Maurillo L, Buccisano F, Venditti A, et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lym-phocytic leukemia. Cancer. 2005;104(12): 2743-52.
29. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophos-phamide in patients with chronic lympho-cytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
30. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comp Statist Data Analysis. 2003;43:121-37.
31. Del Principe MI, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Marini R, et al. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica. 2004;89(12):1468-75.
32. Bomben R, Dal Bo M, Zucchetto A, Zaina E, Nanni P, Sonego P, et al. Mutational status of IgV(H) genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection? Leukemia. 2005;19(8):1490-2.
33. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute Sponsored Working Group Guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-7.
34. Zucchetto A, Bomben R, Dal Bo M, Sonego P, Nanni P, Rupolo M, et al. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lym-phocytic leukemia. J Cell Physiol. 2006; 207(2):354-63.
35. D'Arena G, Nunziata G, Coppola G, Vigliotti ML, Tartarone A, Carpinelli N, et al. CD38 expression does not change in B-cell chronic lymphocytic leukemia. Blood. 2002;100(8):3052-3.
36. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609-14.
37. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005;105(5): 2036-41.
38. Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112 (3):782-92.
39. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-{kappa} B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117 (2):563-74.
40. Simms PE, Ellis TM. Utility of flow cyto-metric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation. Clin Diagn Lab Immunol. 1996;3(3):301-4.
41. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 2006;440(7083):540-4.
42. Kishimoto TK, Jutila MA, Butcher EC. Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule. Proc Natl Acad Sci USA. 1990;87(6):2244-8.
43. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007;110(9):3352-9.